Abstract Endometrial cancer (EC) is the fourth most frequent cancer in women in Europe, and as its incidence is increasing, prevention strategies gain further pertinence. Risk prediction models can be a useful tool for identifying women likely to benefit from targeted prevention measures.
Introduction
Endometrial cancer (EC) is the fourth most frequent cancer in women in Europe [1] . Most cases are diagnosed in older women, often after 60 years of age. Although EC is frequently diagnosed at an early stage when the disease is curable, about one fifth of all cases have a poor prognosis [1] . Well-established risk factors for EC include obesity, use of estrogen-only hormone replacement therapy (HRT) and polycystic ovary syndrome, whereas the use of combined estrogen-plus-progestin HRT and oral contraceptives (OC) are protective [2] [3] [4] [5] [6] [7] [8] . As the number of women living to an older age is steadily growing, together with the prevalence of obesity and sedentary lifestyles, the number of EC cases is also expected to increase in the near future [9] . In view of these developments, prevention strategies gain further pertinence. Information on a woman's risk of developing EC within the next 5 years derived from valid risk models can help physicians to motivate or proactively propose targeted clinical prevention measures such as the preventive use of progestin-based hormonal treatments [10] . Risk models may help balance expected benefits against possible harms of preventive treatments and can also be a useful tool for selecting women who may benefit from screening programs [11, 12] .
Recent investigations based on the prospective EPIC cohort have confirmed associations for several risk factors with EC, including reproductive factors [5] , use of estrogen-alone versus estrogen-plus-progestin HRT [4] , excess body weight [13] , physical inactivity [14] , and cigarette smoking, which may have different effects in pre-and post-menopausal women [15] . Taken together, these findings from the EPIC cohort led to the development of a risk prediction model for EC, combining the predictive capability from all of these risk factors. The availability of full prospective cohort data allowed direct estimation of absolute risk levels, and the large cohort size and number of incident cases of EC allowed application of robust methods for model building and assessment of discriminative capacity and calibration of absolute risk estimates.
Methods
The EPIC cohort
Study participants and baseline data collection
The European Prospective Investigation into Cancer and Nutrition (EPIC) is a multicenter, population-based cohort study including more than 520,000 participants (367,903 women), enrolled into the cohort between 1992 and 2000 in 23 study centers across 10 different countries (i.e. Denmark, France, Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden and United Kingdom). The cohort population and data collection procedures have been described in detail elsewhere [16] . All participating women completed questionnaires on their diet, lifestyle, menstrual and reproductive histories, and medical history. All study participants provided written informed consent, and the local ethical review boards of the participating institutions gave approval for the studies.
In most countries, height and weight were measured at recruitment according to standardized protocols. However, in EPIC-Oxford and approximately two-thirds of the French cohort, height and weight were self-reported. Body mass index was calculated as weight (kg)/height (m) 2 . Data from the recruitment questionnaire included age at menarche, age at first and number of full-term pregnancies, duration of OC use, and for postmenopausal women additional questions addressed age at menopause and past or current HRT use. Women were considered premenopausal at baseline, if they reported having had regular menses over the past 12 months or if they were \46 years of age. Women who reported a bilateral ovariectomy or not having had any menses over the last 12 months or who were over 55 years old at recruitment were considered postmenopausal. Women between 46 and 55 years of age at recruitment with missing or incomplete questionnaire data on menopausal status were classified as peri-menopausal/unknown. Information on menopausal hormone-use at recruitment was used as indicator of ever use and cumulative duration.
Smoking behavior at baseline was summarized into categories of never, former, current or unknown. School level was considered a proxy for socioeconomic status. Information on self-reported diabetes, hypertension and hyperlipidemia at baseline was recorded in categories of yes, no and unknown.
Prospective ascertainment of cancer endpoints and vital status
Incident cancer cases were identified through several methods, including record linkage with regional cancer registries (Denmark, Italy, The Netherlands, Spain and the United Kingdom), linkage to health insurance records, active follow-up of study subjects and systematic requests of patient records from pathology registries (France, Germany and Greece) [16] . Data on vital status were obtained from mortality registries at the regional or national level.
Statistical analyses

Exclusions
Participants who had reported hysterectomy (N = 39,953), a prevalent cancer (except non-melanoma skin cancer) at the time of recruitment (N = 15,317), or with missing follow-up data (lost to follow-up immediately after recruitment; N = 2591), were not considered in the analyses. Data from Norway and Sweden (N = 61,119) were excluded, because several risk variables of interest had not been collected. Information on incident hysterectomy during follow-up was not available for this analysis. Simple imputation of sporadic missing values allowed us to use 201,811 participants with complete covariate data (81 % of all eligible subjects).
Statistical model
To derive an age specific absolute risk score from a number of risk factors we first developed a relative risk score. This relative risk score was used to calculate country-and agespecific baseline risk of EC. In a competing risk model these estimates were then combined with estimates for risk of hysterectomy and of developing other forms of primary cancer or death during follow-up, as detailed below.
Factors previously associated with EC risk in EPIC [4, 5, [13] [14] [15] were modeled in a Cox proportional hazards model with age as underlying time scale, starting observation at recruitment and ending at EC diagnosis or censored at end of follow-up or other event (death, other cancer). This analysis was stratifyed by center and age at recruitment in one-year increments. All factors previously associated with EC risk and all relevant interactions were combined into this model, together with potential confounders: menopausal status, BMI (continuous), interaction of BMI with menopausal status, age at first full term pregnancy (FTP) (centered at median age 24, nulliparous women coded 0), number of FTP in categories nulliparous, one, two, three or more, age at menarche (centered at median age 13), OC use, duration of OC use, interaction of OC use with BMI (for interaction regarded in categories normal: BMI \ 25, overweight: 25 B BMI \ 30 and obese: BMI C 30), age at menopause (centered at median age 50, pre-/peri-menopausal women coded as 0), HRT use, duration of HRT use, interaction of HRT use with BMI (categorical), smoking status and interaction of smoking status with menopausal status, alcohol consumption with interaction with menopausal status, diabetes, hypertension and hyperlipidemia, physical activity and highest educational level.
A backwards elimination procedure was implemented, with inclusion criterion set to p = 0.1. Linear shrinkage based on 100 bootstrap samples was applied to limit overfitting. The resulting ''shrunk'' parameter estimates were combined with the individuals' observed values into a onedimensional relative risk score.
For the estimation of absolute risks of developing EC, the relative risk score was included into the estimation of a piece-wise-constant exponential baseline hazard function (including calibration parameters for country of origin), using 5-year age intervals as the underlying time-scale. Consistently with the Cox model described above, women who died or had another first primary incident cancer were censored at their age of that event. From the women's baseline data on prevalent hysterectomy and the age at which hysterectomy had been performed, we also estimated age-and country-specific risks of having a hysterectomy. These risk estimates were combined into a cause-specific competing risk model [17] for EC risk (probability p(a, b, x), i.e. cumulative incidence to develop EC between age a and b with individual risk factor combination x) as summarized in formula (1):
In this equation
Þ represents the cause specific risk of EC calculated as product of (piecewise constant) baseline hazard k 1_a in age-interval a, the constant factor b 1,country to account for differences in incidence rates between countries, and the relative risk score derived from the Cox-model as rr
The (piecewise constant) competing hazards for death or other cancer k 2 ¼ k 2 a Á b 2;country and for hysterectomy k 3 ¼ k 3;a;country were computed without further covariates. Absolute risk estimates over 5 years were calculated for each woman, based on her age and exposure profile at entry and on the estimates from the relative risk model and the age-and country-specific hazards model. Software written in SAS to compute absolute risk estimates for any age, projection length, and combination of risk factors is available for download as online resource.
Assessment of model quality
Five-fold cross-validation was applied to our modeling processes to obtain unbiased results on model quality on data portions that had been kept aside from model building steps. Discriminative quality was evaluated with an extension of the area under the ROC-curve statistic (AUROC), the concordance statistic 'Overall C' [18] . The integrated discrimination improvement (IDI) index [19] was used to examine the improvement in discrimination between the epidemiologic risk model and a model based on age and country alone. Calibration of absolute risk estimates was assessed as the ratio of expected to observed cases overall. The Hosmer-Lemeshow test [20] was used to evaluate model calibration over deciles of the risk score. All these analyses were stratified by country, and all were generated using SAS (9.3) software.
Results
The distribution of the risk factors in the study data and characteristics of incident cases of EC are presented in Table 1 . The women's median age at recruitment was 50 years (95 % were between age 27 and 68). The median follow-up of the study was 11.7 years (range\1-16 years), and 855 incident cases of EC were diagnosed at median age at diagnosis of 61 years (2.5th-97.5th range 46-76 years). Other incident cancers were diagnosed in 11,384 women, and 5142 women died without developing cancer. At recruitment the women's BMI was on average 24 kg/m 2 . Forty-five percent (45 %) of the women were premenopausal, 39 % were postmenopausal at baseline. For postmenopausal women the median age at menopause was 50 years. The majority (59 %) of women had used OC, and about 14 % were former or current HRT users, 2 % reported that they had diabetes, 17 % hypertension and 13 % hyperlipidemia. Eighteen percent were current smokers, 21 % were former smokers and 60 % had never smoked.
After backwards elimination, the following variables were selected into the prediction model: BMI (continuous), age at menopause and duration of HRT-use, each increasing the risk with increasing values; age at menarche, duration of OC use (years) by BMI category of lean (BMI \25), overweight (BMI 25-\ 30) or obese women (BMI C 30), parity, age at first full term pregnancy, each decreasing the risk with increasing values, menopausal status and smoking status (smoking reduced risk among postmenopausal women). Hazard ratios (HR) are presented in Table 2 . Overall, there was a five-fold difference in relative risk between the women in highest and lowest quintiles of the age-adjusted relative risk score (95 %-CI 3.86-6.56).
In terms of absolute risk estimates, Fig. 1 shows the agespecific percentiles of estimated five-year risk of EC. The 80th percentile of the women's 5-year probability of developing EC varied from 0.23 % at age 50-55 to 0.46 % at age 65-70, and for women within the lowest 20 % of risk the corresponding age-specific 5-year probabilities were below 0.07 and 0.11 %, respectively. For women with the worst risk score (i.e. highest BMI category, early age at first period, no OC-use, nulliparous, using HRT for 13 years and a non-smoker) the predicted five-year risk is 1.6 % at age 50 and 4.2 % at age 65. The full relative risk score based on the coefficients indicated in Table 2 is in the ''Appendix''. A risk model based on age as the only predictor showed a C-statistic of 71 % (95 % CI 64-77 %). The full epidemiologic risk model showed a C-statistic of 77 % (95 % CI 68-85 %), and provided a significantly better overall discrimination than the model based on age only, as indicated by an IDI index of 0.18 % (95 % CI 0.04-0.3 %).
The absolute risk model predicted a total of 313 EC cases to occur in our cohort within 5 years after recruitment whereas 317 were observed during that time (expected-to-observed [E/O] ratio of 0.99). The HosmerLemeshaw test showed no significant deviation from the null hypothesis of good model fit (p = 0.08). Plots of observed versus predicted risk by age and by country showed generally good internal calibration (Fig. 2) . Moreover, in each country the observed and predicted risk estimates from our cohort data showed a fair degree of concordance with age-specific incidence rates from regional cancer registries [21] (Fig. 2) .
Discussion
We developed an epidemiologic risk model for the prediction of women's individual probabilities of developing EC within a Western European population. Overall, our model provides significant discrimination between groups of women at high and low risk to develop EC, and its overall discrimination capacity (C-statistic) of about 77 % is better than what is currently reported for prediction models of breast cancer (53-66 %) [22, 23] . Although a large part of the overall discrimination capacity is based on a woman's age (C = 71 %), the information on the selected risk factors of BMI, reproductive history and exogenous hormone use does provide substantial improvement to the prediction of EC risk.
Only one other epidemiologic model for the prediction of absolute risk of EC has recently been developed by Pfeiffer et al. [24] , using data from three large prospective cohort studies in the US. The risk factors in that model largely overlap with ours, although some differences also exist. Because our cohort includes a considerable proportion of younger women we could derive risk estimates for women from the age of 40. Our selected model also included interaction terms of BMI with OC use, and of smoking with menopausal status. Comparing Pfeiffer's model with ours on the eligible part (in terms of age-range and concurring variable definition) of EPIC cohort data resulted in an overall C-statistic of 66.8 % (95 %-CI 63.5-70.2 %) and 69.9 % (95 %-CI 61.7-78.0 %) respectively, indicating similar discrimination capacity for both models. However, with a ratio of expected to observed cases of 2.4, Pfeiffer's model was poorly calibrated to our cohort (on this data subset our model showed an E/O ratio of 0.98). Since that model had been developed and validated on US-cohort data, we would expect our model to perform equally poorly on the US populations studied by Pfeiffer et al. The issue of model performance in the light of population variation is addressed in greater detail in supplementary materials available as online resource.
An important use of cancer risk prediction models in preventive oncology is the identification of high-risk individuals who may benefit from targeted interventions such as chemopreventive treatments or screening programs. By focusing these types of intervention on high-risk individuals it is often possible to improve the balance between benefits (prevention of cancer; improved chances of cure after early detection) and harms (e.g. treatment side-effects; false-positive screening diagnoses) [11] . With regard to EC, one conceivable type of chemopreventive treatment is the use of progestins [7, 8, 10] in the form of combined OC [25] , or progestin-based alternatives such as a depot of medroxyprogesterone acetate (MPA) [26] or a levonorgestrel-releasing intra-uterine system (LNG-IUS) [27] . Regarding EC screening, existing modalities include measurement of endometrial thickness by trans-vaginal ultrasound sonography (TVS) and concurrent endometrial biopsy [28] . Recent observational data from a large-scale cohort in the United Kingdom provided some indication of the utility of targeted screening high-risk groups [12] . Limiting TVS screening to a higher risk group selected on the basis of epidemiologic risk factors improved sensitivity and specificity to 84 and 90 % respectively, and calculations showed that 40 % of EC cases could have been diagnosed by screening only 25 % of the population.
Whereas the prospective cohort design and the large size of the EPIC cohort and EC case numbers are major strengths, our study also has potential limitations. First of all, our study lacked information on several major risk factors, both at baseline and during prospective follow-up. This includes information on polycystic ovary syndrome, which among premenopausal women is associated with an approximate three to five-fold increase in EC risk before menopause [6, 7] and rates of hysterectomy during the follow-up period. Although our absolute risk models were adjusted for estimates of age-and country-specific rates of hysterectomy, the lack of incident hysterectomy data at the individual level has likely led to some reduction in the discriminating capacity of our model. A second possible limitation of our study is that we did not have complete information on the types of HRT used. Furthermore, we had no complete information on histological classification of endometrial tumors. Our prediction model likely estimates risk predominantly for the development of type-I (endometrioid) tumors, which represent about 85 % of all EC occurrences.
External validation of our model on independent data remains open. However, both model building and estimation were separated from validation via cross-validation. Our model showed good internal calibration of absolute risk estimates as compared to observed incidence rates within the EPIC cohorts. Comparisons of cohort-specific estimates with incidence rates from local cancer registries showed modest discrepancies in some of the EPIC countries (Fig. 2) . In a detailed examination of model performance in EPIC subcohorts we have estimated the variation of discrimination and calibration in different European populations (online resource). We find a strong heterogeneity between populations originating from different countries in crude incidence rates and in the country-effects estimated in our parametric model, which are adjusted for the EC-risk factors. Thus, a calibrating constant appears to be necessary to achieve good model validity for each individual country. External validation in a single external cohort may not be sufficient to assess general validity of such an EC-risk model, as can also be seen from the results of Pfeiffer's model applied to our cohorts. Hence we propose that in general the question of model calibration may be best assessed by estimating heterogeneity of model performance in diverse cohort populations.
EPIC cohort participants may not perfectly represent the population at large. This does not put the validity of our risk model into question, but it does restrict interpretation of our data with regard to the exact percentile distribution of women in the general population that may reach given absolute risk thresholds. This epidemiologic risk model could be extended using information on possible (pre-) clinical symptoms, in particular postmenopausal vaginal bleeding symptoms, previous breast cancer and tamoxifen use [29] , factors that are all likely to further discriminate women by the likelihood of developing, or already having EC. Another possible extension is the additional use of serum-based biomarkers of EC risk, such as endogenous hormones [30, 31] or biomarkers for early tumor detection [32] .
As our model seems well calibrated with good discriminative capacity, we propose it could be used as first Fig. 2 Country and age-specific annual EC risk as observed and predicted in our cohort, compared with rates from registries step in a multilevel prevention procedure and thus builds an important resource for further research on the prevention of EC in the general population in Western Europe. The observed population variation in EC-risk and EC-risk model performance suggests that a large-scale world-wide cohortconsortium approach would be needed to assess and adjust for the population variation, to achieve an EC-risk model with general validity.
